Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
A new population study reveals that relatively mild forms of the HD mutation are much more common than we thought
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!